Drug Discovery World

FEBRUARY 13, 2024

AM1476, a first-in-class, peripheral-acting serotonin receptor antagonist, has been granted US and EU Orphan Drug Designation as an anti-fibrotic treatment for systemic sclerosis. It has demonstrated efficacy in in vitro and in vivo models of fibrosis, as well as favourable safety and pharmacokinetic profiles in Phase I clinical studies.

Drugs 52

Drugs In-Vivo In-Vitro Medicine 52

Pharmaceutical Technology

MAY 5, 2023

TFF Pharmaceuticals and NIEHS will investigate the TFF-HMW-HA formulations’ therapeutic efficacy and pharmacokinetics using in vitro and in vivo models of respiratory diseases.

Development 162

Development In-Vivo In-Vitro Engineer 162

Pharmaceutical Technology

NOVEMBER 4, 2022

The staff in the US from the acquired business will be retained by Reaction to set up its presence in Hershey, which comprises in vitro and in vivo expertise. The staff in the US from the acquired business will be retained by Reaction to set up its presence in Hershey, which comprises in vitro and in vivo expertise.

In-Vivo 130

In-Vivo In-Vitro Genetics Drugs 130

Drug Discovery World

APRIL 21, 2023

New study results have demonstrated the potential of a new drug to reprogramme the immune profile in the tumour microenvironment (TME) and convert resistant tumours to responders to Immune Checkpoint Blockage (ICB) therapies. The post New drug could help overcome tumour resistance to treatment appeared first on Drug Discovery World (DDW).

Drugs 98

Drugs In-Vivo In-Vitro Protein 98

Drug Discovery World

JUNE 8, 2023

Grown in vitro, these cells can provide patient specific human brain models from a large cohort of AD patients – to create a ‘clinical trial in a dish’. The recent US Federal Food and Drug Administration Agency (FDA) Modernization Act 2.0

Clinical Trials 97

Clinical Trials Clinical Trials Trials In-Vitro 97

Drug Discovery World

MAY 1, 2023

Download Emulate’s Introduction to Organ-on-a-Chip Technology eBook to learn about: What Organ-Chips are, how they work, and why they are transforming the way drugs are discovered and developed How Organ-Chips overcome the main challenges of conventional in vivo and in vitro models The wide variety of insights and endpoint analyses Organ-on-a-Chip (..)

In-Vivo 52

In-Vivo In-Vitro Gene Therapy Gene 52

Drug Discovery World

APRIL 24, 2024

The strategic partnership will combine Variant Bio’s genomic discovery capabilities and VB-Inference platform with Evotec’s knowledge of antifibrotic drug discovery. The strategic partnership will combine Variant Bio’s genomic discovery capabilities and VB-Inference platform with Evotec’s knowledge of antifibrotic drug discovery.

Development 52

Development In-Vivo In-Vitro Genome 52

Drug Discovery World

JANUARY 3, 2023

Mersana Therapeutics and a subsidiary of Merck have entered a research collaboration to discover novel Immunosynthen antibody-drug conjugates (ADCs) directed against up to two targets. . The post Research partners hope to develop novel antibody-drug conjugates appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Development Research Drugs 52

Drug Discovery World

JUNE 6, 2023

(retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies. ” The post BenevolentAI progresses drug for the potential treatment of ALS appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs In-Vivo In-Vitro Clinical Development 52

Drug Discovery World

APRIL 8, 2024

Following this, Benjamin Cravatt, Professor and the Norton Gilula Chair in Biology and Chemistry at The Scripps Research Institute, discussed activity-based protein profiling (ABPP) and its use in discovering drug candidates for cancer-relevant proteins.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Drug Discovery World

APRIL 5, 2023

Italian research institute and contract research organisation IRBM has become the only company from outside the United States to join cancer drug discovery network the Chemical Biology Consortium (CBC). The post Only non-US company joins cancer drug discovery consortium appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

pharmaphorum

FEBRUARY 13, 2022

German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

Drug Discovery World

JUNE 26, 2023

Select monoclonal IgG4 antibodies, re-engineered from human IgE antibodies, were able to inhibit allergic plasma IgE from binding recombinant Ara h 2 in vitro, and also inhibit whole peanut-mediated mast cell and basophil activation. appeared first on Drug Discovery World (DDW).

Allergies 52

Allergies Antibody In-Vivo In-Vitro 52

Drug Discovery World

JUNE 30, 2023

Research tools, safety testing and regenerative medicines – these endless stem cell applications are powering precision, speed, and new modalities in drug development. Stem cells for use in drug discovery Stem cells are fast becoming an invaluable tool in the drug discovery process.

Development 52

Development Drugs In-Vitro Gene Therapy 52

Drug Discovery World

MAY 1, 2023

The post New eBook: An introduction to organ-on-a-chip technology appeared first on Drug Discovery World (DDW).

In-Vivo 52

In-Vivo In-Vitro Gene Therapy Gene 52

Drug Discovery World

MAY 9, 2023

Jantzen Sperry , PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. Fewer than 5% of oncology drugs that enter clinical trials in the US receive US FDA approval.

Development 52

Development Drugs In-Vivo Clinical Trials 52

Drug Discovery World

APRIL 25, 2023

Download our mitochondrial toxicity infographic and discover the benefits of novel in vitro strategies for consumer safety. Drug-induced mitochondrial dysfunction has been linked to compound attrition, organ toxicity, black-box warnings, and market withdrawals. Understand the importance of testing in early-phase drug discovery.

In-Vitro 52

In-Vitro Drugs Marketing In-Vivo 52

Drug Discovery World

APRIL 25, 2023

Download this new mitochondrial toxicity infographic by Agilent and discover the benefits of novel in vitro strategies for consumer safety. Drug-induced mitochondrial dysfunction has been linked to compound attrition, organ toxicity, black-box warnings, and market withdrawals. Download now.

In-Vitro 52

In-Vitro Drugs Marketing In-Vivo 52

Pharmaceutical Technology

MAY 24, 2023

to investigational new drug-enabling trials, expected in 2024, to treat aggressive diffuse large B-cell lymphomas (DLBCLs). Morphogenesis is targeting a newly identified delta receptor on myeloid-derived suppressor cells (MDSCs) using its new bi-functional antibody-drug conjugates (ADCs) class.

Gene Therapy 130

Gene Therapy In-Vivo In-Vitro Immune Response 130

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. In vivo, METTL1 inhibitors induce tumour growth inhibition in both immune-deficient and immune-competent mouse strains. MT: What data did you present at the conference?

RNA 64

RNA In-Vivo In-Vitro DNA 64

Drug Discovery World

JANUARY 23, 2023

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care. In addition, they discovered that cladribine, a clinical drug, activates DGKB and inhibits DGAT1. GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

Drug Discovery World

AUGUST 3, 2023

Founded in 2011, the company delivers discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology. Previous acquisitions were Peak Proteins in April 2022 and SB Drug Discovery in January 2023.

In-Vivo 52

In-Vivo In-Vitro Protein Marketing 52

Drug Discovery World

OCTOBER 25, 2023

Data generated by our laboratory across in vitro and in vivo models and from human clinical samples support this important finding. Previous attempts to interrupt TGF-β pathway signaling in cancer have been thwarted by activation of alternative resistance pathways by the tumour.

Research 52

Research In-Vivo In-Vitro Clinical Development 52

Drug Discovery World

JANUARY 25, 2024

The research will include studies to assess the effects of Vaxxinity’s active immunotherapies on undisclosed proteins implicated with bone and muscle growth through in vitro and in vivo experiments, and animal models established by UCF.

Medicine 52

Medicine Research In-Vivo In-Vitro 52

Drug Discovery World

OCTOBER 20, 2022

Aqemia has raised €30 million in a Series A funding round to further support its mission to massively scale drug discovery through a first-in-class technological platform combining quantum-inspired physics and machine learning. . We are continuously recruiting to address our next technology and drug discovery challenges”, she added. .

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

pharmaphorum

AUGUST 10, 2020

Gilead has filed its COVID-19 drug remdesivir with the FDA, to treat patients with severe disease, under the brand name Veklury. The drug is currently available to US patients under an Emergency Use Authorisation for treatment of hospitalised patients with severe COVID-19. Feature image courtesy of Rocky Mountain Laboratories/NIH.

Drugs 85

Drugs In-Vivo Contract Manufacturing In-Vitro 85

Drug Discovery World

MARCH 8, 2023

Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2. Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with advanced solid tumours.

Trials 52

Trials In-Vivo In-Vitro Antibody 52

Drug Discovery World

JUNE 27, 2023

The post IRBM and Merck extend peptide therapeutics collaboration appeared first on Drug Discovery World (DDW). Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area.

In-Vivo 52

In-Vivo In-Vitro Engineer Protein 52

Drug Discovery World

OCTOBER 13, 2022

The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK. Drug Discovery 2022: The numbers . Drug Discovery 2022: The numbers . Of those delegates, 75% work in drug discovery.

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Drug Discovery World

JUNE 19, 2023

Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate. This investment from the AFB FII fund stems from the AdBio-Inserm Transfert partnership announced in May 2022 to finance, support and grow Europe’s most innovative life science startups.

Development 52

Development Life Science In-Vivo In-Vitro 52

Drug Discovery World

JANUARY 31, 2024

Breye is developing novel, oral ophthalmology drugs fordiabetic retinopathy (DR) or age-related macular degeneration (AMD).

Clinical Trials 52

Clinical Trials Clinical Trials In-Vivo In-Vitro 52

Drug Discovery World

APRIL 20, 2023

Monitoring neuronal morphology in long-term in vitro cell cultures is critical for characterisation and evaluation of disease models and to understand neuronal development. Ideally, approaches to track neurite dynamics would allow continuous automated measurements of structural parameters, including neurite length and number of branch points.

In-Vitro 52

In-Vitro In-Vivo Development Drugs 52

Drug Discovery World

APRIL 20, 2023

Monitoring neuronal morphology in long-term in vitro cell cultures is critical for characterisation and evaluation of disease models and to understand neuronal development. The post App Note: Kinetically quantify neuronal outgrowth appeared first on Drug Discovery World (DDW).

In-Vitro 52

In-Vitro In-Vivo Development Drugs 52

The Pharma Data

MAY 3, 2021

In its 2020 annual report, the division of the US Food and Drug Administration (FDA) tasked with addressing emerging regulatory issues and developing new tools and approaches for regulatory reviews said it was able to expand its efforts despite the COVID-19 pandemic impacting most of the year. . Posted 03 May 2021 | By Michael Mezher .

In-Vitro 52

In-Vitro Clinical Trials Clinical Trials In-Vivo 52

The Pharma Data

JANUARY 6, 2021

The research collaboration is aimed at identifying novel lead compounds and repurposing existing drugs for rheumatoid arthritis and nonalcoholic steatohepatitis, leveraging Standigm’s AI-powered drug discovery platforms : Standigm BEST , Standigm Insight , and Standigm ASK. Standigm is an AI-driven drug discovery company.

FDA Approval 52

FDA Approval Life Science Drugs In-Vivo 52

pharmaphorum

FEBRUARY 19, 2021

Snipping out this viral code with powerful CRISPR gene editing technology, which last year won Drs Emmanuelle Charpentier and Jennifer Doudna the Nobel Prize for chemistry, would in theory prevent the need for drugs to suppress the virus and the development of AIDS.

Gene Editing 105

Gene Editing In-Vivo DNA In-Vitro 105

Drug Discovery World

OCTOBER 27, 2023

Organ-chips combine cell culture with microfluidics to emulate the biological forces of different organ tissues and/or disease states, allowing pharmaceutical researchers to determine a drug candidates’ efficacy and toxicity ahead of clinical trials. Could organ-chips replace other research methods? Not yet, according to Ewart.

Research 72

Research Gene Therapy In-Vivo In-Vitro 72